Join the club for FREE to access the whole archive and other member benefits.

Tamar Ben-Yedidia

Chief Scientific Officer of BiondVax pharmaceuticals Ltd

Dr. Tamar Ben-Yedidia has more than 15 years of experience in the field of Immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd, BTG (Rehovot), working on the development of a recombinant Hepatitis-B vaccine.

She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax.

Dr. Ben-Yedidia was involved in two European Consortium projects related to evaluation of different approaches for vaccination in which leading laboratories in the field participated. Dr. Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.

Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”.

Visit website: https://www.biondvax.com/about-us/management/tamar-ben-yedidia-cso/

 tamarbenyedidia

See also: Company BiondVax - BiondVax Pharmaceuticals Ltd is Phase 3 clinical phase biopharmaceutical company developing the Universal Flu Vaccine

Details last updated 15-Dec-2019

Tamar Ben-Yedidia News

2020 could bring universal flu vaccine thanks to Israeli researchers

2020 could bring universal flu vaccine thanks to Israeli researchers

Algemeiner - 11-Dec-2019

It's always better to be prepared beforehand for another possible pandemic